"U.S. Compounding Pharmacies Market for Topical product segment to Grow at 5.3% CAGR by 2024"|Baxter,Fagron,Fresenius Kab,ICU Medical,

Topical product segment is estimated to witness 5.3% CAGR over the analysis timeframe owing to increasing demand for topically administered drugs such as muscle relaxants, anti-inflammatories and anesthetics prescribed for pain management and inflammation therapy.

U.S. Compounding Pharmacies Market size is set to exceed USD 7 billion by 2025.Growing prevalence of chronic diseases in the U.S. such as cancer, diabetes, cardiovascular disease, respiratory diseases and obesity will drive the U.S. compounding pharmacies market growth over the forecast period. Increasing drug shortage in the country due to production delays and unavailability of previously manufactured drugs in the market will surge the demand of compounded drugs. Timely availability of compounded drugs in the treatment of cardiac or other emergency conditions will thus foster the U.S. compounding pharmacies industry growth.

Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/2961

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:

1. Absolute Pharmacy
2. B. Braun Medical
3. Baxter
4. Cantrell Drug Company
5. Central Compounding Center
6. Clinigen Group
7. Dougherty’s Pharmacy
8. Fagron
9. Fresenius Kabi
10. ICU Medical
11. Institutional Pharmacy Solutions
12. Lorraine’s Pharmacy
13. McGuff Compounding Pharmacy Services
14. McKesson Corporation
15. Nephron Pharmaceuticals
16. Pencol Compounding Pharmacy
17. Pentec Health
18. PharMEDium
19. Premier Pharmacy Labs
20. Rx3 Compounding Pharmacy
21. RXQ Compounding Pharmacy
22. Triangle Compounding Pharmacies
23. Wedgewood Village Pharmacy and Wells Pharmacy Network

Rise in the number of baby boomers susceptible to various chronic and non-communicable disease will render positive impact in the market growth. Ability of compounding pharmacies to formulate liquid dosage for patients with difficulty in swallowing pills and combine certain prescriptions into single dose enables patients to avoid administration of multiple doses. However, safety issues pertaining to compounded drugs coupled with continuously changing regulatory scenario may hamper the adoption of compounded medication thereby rendering negative impact on the business growth.

503B compounding pharmacy segment accounted for USD 2.5 billion in 2017 and is estimated to show lucrative growth over analysis period. The growth is attributable to the ability of these pharmacies to compound mass medication, thereby lowering production costs and increasing customer base.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2961

Non-sterile segment held the highest share of 67.7% in 2017 owing to increasing adoption of oral medication that offers convenience and ease of administration in patients of all age groups. Growing demand for oral liquid preparation and topical medication for pain management and anti-inflammatory therapies will further propel segment growth.

Pediatric application segment held 14.5% market share in 2017 and is estimated to grow significantly during the forthcoming years. Ability of compounding pharmacies to transform standard drugs into flavored dosage and colorful forms will increase its acceptance among the children thereby accelerating the segmental growth.

Pharmaceutical ingredient alteration (PIA) segment accounted for USD 1.7 billion in 2017 owing to rising demand for drugs compounded in accordance with specific patient needs such as hypoallergenic versions of drugs for individuals allergic to certain dyes or preservatives.

Hormone replacement therapeutic segment is anticipated to show CAGR of 5.3% over the forecast period. Compounded hormone replacement therapy can be used specifically to suit individual body and hormone levels. Growing awareness among women regarding compounded bioidentical menopausal hormone therapy (BMHT) will further spur the segment growth.

Browse Complete Summary of this report @ https://www.gminsights.com/industry-analysis/us-compounding-pharmacies-market

Some of the prominent players operating in U.S. compounding pharmacies market are Absolute Pharmacy, B. Braun Medical, Baxter, Cantrell Drug Company, Central Compounding Center, Clinigen Group, Dougherty’s Pharmacy, Fagron, Fresenius Kabi, ICU Medical, Institutional Pharmacy Solutions, Lorraine’s Pharmacy, McGuff Compounding Pharmacy Services, McKesson Corporation, Nephron Pharmaceuticals, Pencol Compounding Pharmacy, Pentec Health, PharMEDium, Premier Pharmacy Labs, Rx3 Compounding Pharmacy, RXQ Compounding Pharmacy, Triangle Compounding Pharmacies, Wedgewood Village Pharmacy and Wells Pharmacy Network. Key industry players are majorly focusing on mergers and acquisitions to broaden product portfolio and capture high revenue share.

About Global Market Insights:

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web: www.gminsights.com

This release was published on openPR.